News & Updates

Nonoptimal temperatures appear to be the cause of several cardiovascular (CV) deaths worldwide, according to a study.

Use of dual therapy with ACE inhibitors and ARBs tends to elevate the risk of renal outcomes in people with or without chronic kidney disease (CKD), reports a study presented at ERA 2024.

A study from Iran presented at ERA 2024 demonstrated the potential of oral tacrolimus to deliver an antipruritic effect in haemodialysis patients with uraemic pruritus.

Higher adherence to the Mediterranean diet confers a 23-percent reduction in the risk of all-cause mortality, a benefit that may be partially explained by potential mediation by several cardiometabolic factors, according to a study.

One in five individuals who attempt suicide do not have a history of psychiatric disorders, a cross-sectional study has shown.

Treatment with tirzepatide for 52 weeks resulted in MASH* resolution, with no worsening of fibrosis in patients with MASH and fibrosis in the phase II SYNERGY-NASH trial.

A twice-weekly haemodialysis schedule does not appear to increase death and hospitalization rates at 2 years compared with a thrice-weekly schedule, although some patients on the biweekly schedule may require medication dose adjustments, as reported in the prospective multicentre nonrandomized TATH* trial.